Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, December 9, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the Ireland Japan Chamber of Commerce (IJCC, http://www.ijcc.jp/) presented it with a business...
Tokyo, November 11, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating that it accepted...
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the recombinant influenza HA vaccine (H5N1) ASP7373 (former code:...
Tokyo, Japan, November 11, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced today that it is signing the United Nations Global Compact1, which will further reinforce the...
Follow us
